Will prostate cancer respond to metabolic-directed treatment?

Article

Chicago-Findings from systematic research being conducted by researchers at the University of California, Davis suggest that arginine deprivation may be a novel treatment in some prostate cancers.

Related Videos
Related Content
Pivotal data for lumasiran in PH1 published in NEJM

Pivotal data for lumasiran in PH1 published in NEJM

April 1st 2021
Article

The ILLUMINATE-A trial of lumasiran in patients with primary hyperoxaluria type 1 supported the FDA approval of this drug.

Nedosiran explored in primary hyperoxaluria type 3

Nedosiran explored in primary hyperoxaluria type 3

February 26th 2021
Article

The RNAi drug nedosiran is a once-monthly subcutaneous injection under investigation for all 3 types of primary hyperoxaluria.

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria

February 9th 2021
Article

FDA new drug application filing expected by the end of 2021.

Site Logo

FDA approves androgen inhibitor for metastatic PCa

September 12th 2012
Article

The FDA recently approved the oral androgen receptor inhibitor enzalutamide (Xtandi) for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel (Taxotere).

Site Logo

Blood test could guide treatment for kidney cancer

August 29th 2012
Article

A common enzyme that is easily detected in blood may predict how well patients with advanced kidney cancer will respond to a specific treatment, according to physicians at Duke Cancer Institute, Durham, NC.

Site Logo

BCG for bladder cancer in short supply

August 22nd 2012
Article

Due to manufacturing issues, a formulation of the bladder cancer treatment bacillus Calmette-Guérin is currently unavailable from one manufacturer.

© 2023 MJH Life Sciences

All rights reserved.